Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

Background: The discovery of low-frequency coding variants affecting the risk of coronary artery disease has facilitated the identification of therapeutic targets.

Methods: Through DNA genotyping, we tested 54,003 coding-sequence variants covering 13,715 human genes in up to 72,868 patients with coronary artery disease and 120,770 controls who did not have coronary artery disease. Through DNA sequencing, we studied the effects of loss-of-function mutations in selected genes.

Results: We confirmed previously observed significant associations between coronary artery disease and low-frequency missense variants in the genes LPA and PCSK9. We also found significant associations between coronary artery disease and low-frequency missense variants in the genes SVEP1 (p.D2702G; minor-allele frequency, 3.60%; odds ratio for disease, 1.14; P=4.2×10(-10)) and ANGPTL4 (p.E40K; minor-allele frequency, 2.01%; odds ratio, 0.86; P=4.0×10(-8)), which encodes angiopoietin-like 4. Through sequencing of ANGPTL4, we identified 9 carriers of loss-of-function mutations among 6924 patients with myocardial infarction, as compared with 19 carriers among 6834 controls (odds ratio, 0.47; P=0.04); carriers of ANGPTL4 loss-of-function alleles had triglyceride levels that were 35% lower than the levels among persons who did not carry a loss-of-function allele (P=0.003). ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13; P=2.0×10(-4)) and a gain-of-function variant that was associated with protection from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio, 0.94; P=2.5×10(-7)).

Conclusions: We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease. (Funded by the National Institutes of Health and others.).

Citing Articles

Comprehensive Proteomic Profiling of Exfoliation Glaucoma Via Mass Spectrometry Reveals SVEP1 as a Potential Biomarker.

Li J, Ma Y, Xie L, Zhuo K, He Y, Ma X Invest Ophthalmol Vis Sci. 2025; 66(3):19.

PMID: 40052860 PMC: 11905629. DOI: 10.1167/iovs.66.3.19.

Deep plasma and tissue proteome profiling of knockout mice reveals pathways associated with deficiency.

Maxwell C, Bhakta N, Denniff M, Sandhu J, Kessler T, Ng L J Mol Cell Cardiol Plus. 2025; 11:100283.

PMID: 39895831 PMC: 11782998. DOI: 10.1016/j.jmccpl.2025.100283.

Lipoprotein Lipase: Structure, Function, and Genetic Variation.

Perera S, Wang J, McIntyre A, Hegele R Genes (Basel). 2025; 16(1).

PMID: 39858602 PMC: 11764694. DOI: 10.3390/genes16010055.

Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP.

Osawa I, Akita K, Hasegawa K, Fifer M, Tower-Rader A, Reilly M Circ Heart Fail. 2025; 18(2):e012343.

PMID: 39831317 PMC: 11835532. DOI: 10.1161/CIRCHEARTFAILURE.124.012343.

Competitive displacement of lipoprotein lipase from heparan sulfate is orchestrated by a disordered acidic cluster in GPIHBP1.

Biswas A, Arshid S, Kristensen K, Jorgensen T, Ploug M J Lipid Res. 2025; 66(2):100745.

PMID: 39814316 PMC: 11869522. DOI: 10.1016/j.jlr.2025.100745.

References

Abifadel M, Varret M, Rabes J, Allard D, Ouguerram K, Devillers M . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154-6. DOI: 10.1038/ng1161. View

Nakada T, Russell J, Boyd J, Thair S, Walley K . Identification of a nonsynonymous polymorphism in the SVEP1 gene associated with altered clinical outcomes in septic shock. Crit Care Med. 2014; 43(1):101-8. DOI: 10.1097/CCM.0000000000000604. View

Mailly F, Tugrul Y, Reymer P, Bruin T, Seed M, Groenemeyer B . A common variant in the gene for lipoprotein lipase (Asp9-->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1995; 15(4):468-78. DOI: 10.1161/01.atv.15.4.468. View

Cohen J, Boerwinkle E, Mosley Jr T, Hobbs H . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354(12):1264-72. DOI: 10.1056/NEJMoa054013. View

Romeo S, Pennacchio L, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs H . Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007; 39(4):513-6. PMC: 2762948. DOI: 10.1038/ng1984. View

Desai U, Lee E, Chung K, Gao C, Gay J, Key B . Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A. 2007; 104(28):11766-71. PMC: 1913890. DOI: 10.1073/pnas.0705041104. View

Kathiresan S . A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med. 2008; 358(21):2299-300. DOI: 10.1056/NEJMc0707445. View

Folsom A, Peacock J, Demerath E, Boerwinkle E . Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Metabolism. 2008; 57(11):1591-6. PMC: 2707767. DOI: 10.1016/j.metabol.2008.06.016. View

Talmud P, Smart M, Presswood E, Cooper J, Nicaud V, Drenos F . ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol. 2008; 28(12):2319-25. DOI: 10.1161/ATVBAHA.108.176917. View

10.

Yin W, Romeo S, Chang S, Grishin N, Hobbs H, Cohen J . Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem. 2009; 284(19):13213-22. PMC: 2676053. DOI: 10.1074/jbc.M900553200. View

11.

Schunkert H, Konig I, Kathiresan S, Reilly M, Assimes T, Holm H . Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43(4):333-8. PMC: 3119261. DOI: 10.1038/ng.784. View

12.

Ehret G, Munroe P, Rice K, Bochud M, Johnson A, Chasman D . Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478(7367):103-9. PMC: 3340926. DOI: 10.1038/nature10405. View

13.

Tan M, Teo Z, Sng M, Zhu P, Tan N . Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res. 2012; 10(6):677-88. DOI: 10.1158/1541-7786.MCR-11-0519. View

14.

Sato-Nishiuchi R, Nakano I, Ozawa A, Sato Y, Takeichi M, Kiyozumi D . Polydom/SVEP1 is a ligand for integrin α9β1. J Biol Chem. 2012; 287(30):25615-30. PMC: 3408197. DOI: 10.1074/jbc.M112.355016. View

15.

Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes T, Thompson J . Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012; 45(1):25-33. PMC: 3679547. DOI: 10.1038/ng.2480. View

16.

Lafferty M, Bradford K, Erie D, Neher S . Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J Biol Chem. 2013; 288(40):28524-34. PMC: 3789953. DOI: 10.1074/jbc.M113.497602. View

17.

Crosby J, Peloso G, Auer P, Crosslin D, Stitziel N, Lange L . Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014; 371(1):22-31. PMC: 4180269. DOI: 10.1056/NEJMoa1307095. View

18.

Jorgensen A, Frikke-Schmidt R, Nordestgaard B, Tybjaerg-Hansen A . Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014; 371(1):32-41. DOI: 10.1056/NEJMoa1308027. View

19.

Do R, Stitziel N, Won H, Jorgensen A, Duga S, Merlini P . Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2014; 518(7537):102-6. PMC: 4319990. DOI: 10.1038/nature13917. View

20.

Gaudet D, Alexander V, Baker B, Brisson D, Tremblay K, Singleton W . Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015; 373(5):438-47. DOI: 10.1056/NEJMoa1400283. View